TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Bought by LPL Financial LLC

LPL Financial LLC lifted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 61.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 185,062 shares of the biopharmaceutical company's stock after acquiring an additional 70,740 shares during the period. LPL Financial LLC owned 0.12% of TG Therapeutics worth $5,570,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of TGTX. Arizona State Retirement System grew its position in TG Therapeutics by 0.9% during the 4th quarter. Arizona State Retirement System now owns 42,639 shares of the biopharmaceutical company's stock worth $1,283,000 after purchasing an additional 364 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of TG Therapeutics by 24.5% during the fourth quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after buying an additional 371 shares during the last quarter. Brookstone Capital Management increased its position in TG Therapeutics by 3.7% in the 4th quarter. Brookstone Capital Management now owns 17,521 shares of the biopharmaceutical company's stock valued at $527,000 after acquiring an additional 624 shares during the period. Daymark Wealth Partners LLC raised its stake in TG Therapeutics by 1.7% during the 4th quarter. Daymark Wealth Partners LLC now owns 41,500 shares of the biopharmaceutical company's stock valued at $1,249,000 after acquiring an additional 689 shares during the last quarter. Finally, New York State Teachers Retirement System lifted its position in TG Therapeutics by 1.9% during the 4th quarter. New York State Teachers Retirement System now owns 43,764 shares of the biopharmaceutical company's stock worth $1,317,000 after acquiring an additional 837 shares during the period. 58.58% of the stock is owned by institutional investors and hedge funds.

Remove Ads

TG Therapeutics Price Performance

TGTX stock traded up $0.73 on Friday, reaching $36.71. 2,052,937 shares of the company's stock were exchanged, compared to its average volume of 3,110,585. TG Therapeutics, Inc. has a twelve month low of $12.93 and a twelve month high of $43.32. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27. The stock has a fifty day moving average of $35.76 and a 200-day moving average of $31.39. The firm has a market cap of $5.77 billion, a PE ratio of -367.06 and a beta of 2.14.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, topping analysts' consensus estimates of $0.08 by $0.07. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. As a group, equities analysts predict that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Wall Street Analyst Weigh In

TGTX has been the topic of a number of recent research reports. HC Wainwright reissued a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. StockNews.com upgraded shares of TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, TG Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $40.67.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.